当前位置: X-MOL 学术J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors.
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2020-08-11 , DOI: 10.1021/acs.jmedchem.0c00778
Ahmed Haider 1 , Luca Gobbi 2 , Julian Kretz 2 , Christoph Ullmer 2 , Andreas Brink 2 , Michael Honer 2 , Thomas J Woltering 2 , Dieter Muri 2 , Hans Iding 3 , Markus Bürkler 2 , Martin Binder 2 , Christian Bartelmus 2 , Irene Knuesel 2 , Pal Pacher 4 , Adrienne Müller Herde 1 , Francesco Spinelli 1 , Hazem Ahmed 1 , Kenneth Atz 2 , Claudia Keller 1 , Markus Weber 5 , Roger Schibli 1, 6 , Linjing Mu 1, 6 , Uwe Grether 2 , Simon M Ametamey 1
Affiliation  

Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clinical routine. In this work, we synthesized 15 fluorinated pyridine derivatives and tested their binding affinities toward CB2 and CB1. With a sub-nanomolar affinity (Ki for CB2) of 0.8 nM and a remarkable selectivity factor of >12,000 over CB1, RoSMA-18-d6 exhibited outstanding in vitro performance characteristics and was radiofluorinated with an average radiochemical yield of 10.6 ± 3.8% (n = 16) and molar activities ranging from 52 to 65 GBq/μmol (radiochemical purity > 99%). [18F]RoSMA-18-d6 showed exceptional CB2 attributes as demonstrated by in vitro autoradiography, ex vivo biodistribution, and positron emission tomography (PET). Further, [18F]RoSMA-18-d6 was used to detect CB2 upregulation on postmortem human ALS spinal cord tissues. Overall, these results suggest that [18F]RoSMA-18-d6 is a promising CB2 PET radioligand for clinical translation.

中文翻译:

2,5,6-三取代氟化吡啶衍生物作为放射性配体的大麻素2型受体正电子发射断层显像的鉴定和临床前开发。

尽管大麻素2型受体(CB2)在神经炎症过程中具有广泛的意义,但目前在临床常规治疗中尚缺乏合适的CB2靶向探针。在这项工作中,我们合成了15个氟化吡啶衍生物,并测试了它们对CB2和CB1的结合亲和力。RoSMA-18- d 6的亚纳摩尔亲和力(CB2的K i)为0.8 nM,与CB1相比具有显着的选择性> 12,000,具有出色的体外性能特征,并被放射性氟化,平均放射化学收率为10.6±3.8。 %(n = 16)和摩尔活度范围为52至65 GBq /μmol(放射化学纯度> 99%)。[ 18 F] RoSMA-18- d 6体外放射自显影,离体生物分布和正电子发射断层扫描(PET)所示,CB2具有卓越的CB2属性。此外,[ 18 F] RoSMA-18- d 6用于检测死后人ALS脊髓组织上的CB2上调。总体而言,这些结果表明[ 18 F] RoSMA-18- d 6是用于临床翻译的有前途的CB2 PET放射性配体。
更新日期:2020-09-24
down
wechat
bug